<DOC>
	<DOCNO>NCT01323062</DOCNO>
	<brief_summary>This non-randomized , open-label Phase 1b trial establish safety recommend phase 2 dose ( RP2D ) bavituximab combination pemetrexed carboplatin subject previously untreated stage IV non-squamous non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Bavituximab Plus Carbo Pemetrexed Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer ( NSCLC ) Subjects</brief_title>
	<detailed_description>Subjects measurable disease assess response every 2 cycle therapy use RECIST 1.1 criterion . In addition , progression free survival ( PFS ) , overall survival ( OS ) exploratory biomarkers , image , thrombotic risk parameter evaluate .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Greater equal 18 Histologically cytologically confirm stage IV nonsquamous NSCLC previously treat systemic chemotherapy Evaluable disease clinical radiographic parameter No history concomitant malignancy Adequate organ marrow function Female subject negative urine serum pregnancy ECOG must 0 1 Squamous cell , small cell , mixed histology Known history bleed diathesis coagulopathy Cavitary tumor tumor invade abut large blood vessel Any history thromboembolic event Ongoing therapy oral parenteral anticoagulant Major surgery within 4 week Day 1 treatment Uncontrolled intercurrent disease ( diabetes , hypertension , thyroid disease ) history significant vascular disease Congestive heart failure History condition require antiplatelet therapy Serious non heal wound Known chronic infection human immunodeficiency virus ( HIV ) viral hepatitis Unable unwilling discontinue use prohibit medication Ddimers &gt; 2 x ULN measure 2 separate occasion least 1 day apart</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>chemotherapy naive</keyword>
	<keyword>stage IV non squamous non small cell lung cancer</keyword>
	<keyword>Phase 1b</keyword>
	<keyword>Bavituximab</keyword>
	<keyword>Chimeric 3G4</keyword>
	<keyword>U North Carolina Chapel Hill</keyword>
</DOC>